Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

Related Posts

Cannabis Exposure After Pregnancy and Development of Hypertension in the nuMoM2b Heart Health Study

Dahl CM, Chahine R, Wiener LE, Silver RM, McMillin GA, Catov JM, Chung J, Greenland P, Grobman WA, Hoffman M, Khan SS, Levine L, Pippen[...]

Association of donor heavy alcohol use with graft failure after deceased-donor liver transplantation stratified by donor sex and macrosteatosis in the OPTN/UNOS registry

Han S, Agopian VG, Steggerda JA, Lee J, Kim M, Kim IK, Kwon JH, Sanford A, Lee YT, Yang JD. Association of donor heavy alcohol[...]

Patient Preferences in Hepatocellular Carcinoma Surveillance: A Multi-site Conjoint Analysis

Kao KD, Troost JP, Yang JD, Salgia R, Woolen SA, Mehta N, Hoteit MA, Jalal PK, El Dahan KS, Daher D, Quirk L, Patel N,[...]